Metabolism of Nucleosides and Nucleotides Prodrugs

Author(s): Coralie De Schutter, Maryam Ehteshami, Emily T. Hammond, Franck Amblard, Raymond F. Schinazi*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 45 , 2017

Become EABM
Become Reviewer
Call for Editor


Background: Modified nucleoside and nucleotide analogs are now the cornerstone of antiviral and anticancer chemotherapies. However, these compounds are not active on their own and need, after entering the cell, to be metabolized to their active 5'-triphosphate form.

Methods: Limitations of these metabolic processes led to development of nucleoside/nucleotide prodrugs in which nucleosides are masked with different groups that can be intracellularly cleaved either chemically or enzymatically.

Results: Several prodrug approaches have been successfully developed in order to increase the efficacy, bioavailability, penetration in target organ, and selectivity of nucleoside/nucleotide analogs.

Conclusion: The concept of nucleoside/nucleotide prodrug is now a well-established approach that led to the approval of numerous drugs for the treatment of HIV, HBV, HCV, HSV and cancer.

Keywords: Antiviral agents, prodrug, nucleoside, enzyme, monophosphate, triphosphate.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 16 February, 2018
Page: [6984 - 7002]
Pages: 19
DOI: 10.2174/1381612823666171011104158
Price: $65

Article Metrics

PDF: 60
HTML: 11
PRC: 2